Trial Profile
A Phase 1, Open-Label, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ASLAN004 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Eblasakimab (Primary) ; Eblasakimab (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; First in man
- Sponsors ASLAN Pharmaceuticals
- 23 Jun 2023 According to an ASLAN Pharmaceuticals media release, the company announced the publication of data from the Phase 1a single ascending dose study of eblasakimab,in Clinical Immunology, a bimonthly peer-reviewed journal, supporting eblasakimabs potential as a novel, differentiated treatment for atopic dermatitis (AD).
- 23 Jun 2023 Results published in an ASLAN Pharmaceuticals Media Release.
- 06 Aug 2021 According to an ASLAN Pharmaceuticals media release, data will also be published in the fall edition of the Journal of Investigative Dermatology.